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A 3.4 year-old rhesus macaque weighing 4.5 kg, was suffering from anorexia, acute mucous and bloody
diarrhea. On physical examination, the monkey showed a loss of activity, hunched posture, abdominal
pain, dehydration, mild gingivitis and unclean anus with discharge. Whole blood was collected for the
examination of electrolytes, hematology and serum chemistry; fresh stool was also collected for bacterial
culture. Blood profiles showed leukocytosis (14.5 K/µL) and neutrophilia (11.0 K/µL) on complete blood
cell count and imbalanced electrolytes associated with diarrhea. As a result of bacterial culture, Shigella
flexneri was identified through Mac/SS, IMVIC test, TCBS and VITEK II. Based on these results, this
monkey was diagnosed as having acute enteritis caused by Shigella flexneri. Treatment was performed
with enrofloxacin prior to the isolation of Shigella flexneri to prevent the transmission of disease.
Fortunately, mucus and bloody diarrhea did not persist and general conditions fully recovered. Our
results show that the use of enrofloxacin is effective in controlling Shigella flexneri infection in newly
acquired rhesus monkeys.
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Shigella is gram-negative bacterium that causes bacillary
dysentery in human and non-human primates [1-4]. Shigella
flexneri belonging to the B subgroup of the genus is a well-
known pathogen for primates, chiefly responsible for morbidity
and mortality in colonized monkeys [5]. Bloody diarrhea and
mucus discharge is often accompanied with abdominal pain,
tenesmus, fever, anorexia, weight loss and dehydration. In
colonies of research macaques, Shigella infections are spread
by the fecal-oral route, originating from the addition of animals
that are asymptomatic carriers, either from the wild or from
other colonies [1,6]. In humans, persons traveling in areas
with poor sanitation and crowded conditions become
particularly susceptible to such diseases [7-9]. Importantly,
Shigella is a zoonotic organism which could present in people
working with nonhuman primates or vice versa.
Currently, a vaccine for Shigella has not been licensed in
the United States and the organism quickly becomes resistant
to medication. During the past 10 years, several live, attenuated
oral Shigella vaccines, including the strains WRSs1, WRSs2
and WRSs3, are acceptable candidates for continued
development as human Shigella sonnei vaccines [10]. However,
commercial vaccine of Shigella is not yet used in the clinic
for human and nonhuman primates. Thus, veterinary clinicians
must assume shigellosis by clinical signs and instigate
appropriate therapy or wait 24 to 48 h for the results of
bacterial culture. For this reason, regular screening is necessary
to prevent spreading of this pathogen to other individuals
or colonies.
Recently, China has become one of the major breeders
and suppliers of macaques for the biotech, pharmaceutical
and medical communities worldwide. Also, our requirement
of these animals is increasing in the field of biomedical research.
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Therefore, adequate prevention and prompt treatment of this
pathogen is required to preserve a source of laboratory
nonhuman primates in our country.
Here, we report that a newly acquired rhesus monkey
infected by Shigella flexneri was precisely diagnosed and
successfully treated with enrofloxacin. In addition, prompt
treatment against this pathogen could control the spread of
disease and preserve healthy colonies.
A 3.4-year-old male rhesus macaque, weighing 4.5 kg, was
suffering from anorexia, acute mucous production and bloody
diarrhea. The colony including this monkey was screened
by the exporting country for bacterial and parasitic pathogens,
such as Mycobacterium,  Salmonella,  Shigella, Yersinia and
endo/ecto parasites. This rhesus macaque was imported from
China and finished the legal quarantine process. Then, the
colony including this monkey was acclimating at a laboratory
animal facility which maintained at was 24±4
oC and a relative
humidity of 50±10% with artificial lighting and a 12:12 light-
dark cycle (7:00 AM onset) as well as with 13-18 air changes
per h. This monkey was housed in an individual home cage
and had daily provided food (PS DIET
®, Oriental Yeast Co,
Ltd, Japan and fresh fruits) and unlimited access to water.
The animal was managed by the National Institutes of Health
“Guide for the Care and Use of Laboratory Animals”.
Fresh bloody diarrhea persisted for two days and gradually
increased infrequency and volume, along with a foul smell
(Figure 1A). The perianal region was unclean with a bloody
discharge (Figure 1B). Vital signs recorded were as follows:
body temperature (39.2), heart rate (250 beats/min) and
respiratory rate (44 breaths/min). On physical examination,
the monkey showed a loss of activity, hunched position,
abdominal pain, dehydration and mild gingivitis. Differential
diagnosis included parasitic, bacterial and viral infection. To
rule out these factors, bloody stool was collected immediately
for bacterial culture and then other laboratory tests were
performed. Laboratory profiles revealed leukocytosis (14.5
K/µL) and neutrophilia (11.0 K/µL) on complete blood cell
count as well as hyponatremia (139 mmol/L), hypokalemia
(3.1 mmol/L) and hypochloremia (99 mmol/L) on electrolytes,
and a normal range for serum chemistry. Based on the clinical
signs, presumptive diagnosis was made as dysentery by Shigella,
Vibrio or Campylobacter species. Preferentially, enrofloxacin
(5 mg/kg, sid, intravenous or intramuscular injection) as an
Figure 1. (A) Fresh bloody stool lasting for two days, showed
gradual increases in frequency and volume with a foul smell.
(B) The perianal region was observed with a bloody discharge.
Figure 2. (A) Colorless or black colonies grown on the Mac/
SSa were subcultured in BAP. (B) IMVIC test showed negative
for indole, motility and H2S in SIM broth, negative in citrate and
K/A in triple sugar iron agar. (C) Oxidase-negative result was
seen for colony grown in thiosulfate-citrate-bile-sucrose media.Shigella flexneri infection in rhesus macaque 345
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antibiotic for bacillary dysentery infection was administered
for 3 days; bacterial cultures and parasitic examinations were
also performed. No evidence of parasitic infection was found
in the stool. On the other hand, the bacterial culture results
showed growth of an unidentified organism.
To identify the organism, bloody stool samples were
inoculated on MacConkey/Salmonella-Shigella agar (Mac/SSa)
(Hanil Komed, Seoul, Korea) and incubated at 37
oC. Colorless
or black colonies grown on Mac/SSa were subcultured in
blood agar (Figure 2A). An IMVIC (Hanil Komed) test was
negative for indole, motility and H2S in SIM broth, and negative
in citrate, and K/A in triple sugar iron (TSI) agar (Figure 2B).
Also, colonies grown in thiosulfate-citrate-bile-sucrose (TCBS)
media were negative for oxidase (Figure 2C). Vibrio spp. and
Campylobacter spp. were not detected in mCCDA and TCBS
media. Finally, through the serological grouping using VITEK
II, the organism was identified as Shigella flexneri. Consequently,
the monkey was diagnosed as enterocolitis caused by Shigella
flexneri and was continually treated with enrofloxacin. At post-
onset day 5, bloody diarrhea completely disappeared and
general body conditions recovered.
Asymptomatic carriers are common, especially in new world
monkeys, and bacteriological screening is known to have
low sensitivity [11]. Quarantine stations may perform routine
stool-screening for enteric pathogens and commence antibiotic
treatment, but this does not guarantee that animals remain
free of infection on delivery to a primate facility. Organisms
may continue to be shed intermittently, commonly at times
of stress, such as when animals are in transit [11]. In these
cases, the infected monkey has been examined regularly for
enteric pathogens at the animal’s breeding and pre-embarkation
quarantine facility, and all animals are documented as negative
in the individual records. However, a latent pathogen in this
monkey was revealed at the time of post-transport and post-
quarantine processes.
Clinical symptoms of shigellosis include mucus and bloody
diarrhea, abdominal pain, nausea, vomiting and fever. Affected
monkeys are weak and moderately to severely dehydrated,
and they require prompt medical treatment to correct life-
threatening fluid and electrolyte imbalances [12]. Fortunately,
this monkey showed rapid recovery from the illness without
electrolyte correction.The enteric pathogen Shigella flexneri
has also been implicated as a cause of periodontal disease
[13,14]. This animal also showed mild gingivitis at both the
upper/lower periodontal region, but has since been
terminated. Diagnosis was based on clinical signs and isolation
of the organism from deep rectal swabs and fresh stool
specimens. Culture and isolation of the organism is facilitated
by the use of selective media such as selenite broth and
SSa agar [15].
Currently, no Shigella vaccine has been licensed, although
several are under development [16-20]. China does not
vaccinate for laboratory nonhuman primate colonies. For that
reason, there is very high potential that asymptomatic carriers
may spread pathogens to other monkeys or colonies. In this
case, the infected monkey was newly imported from China
and just finished the quarantine process when it showed
clinical signs. It is suspected that asymptomatic monkeys reveal
clinical signs by transport or environmental stress.
In this case, treatment of shigellosis was performed very
rapidly and was completed by enrofloxacin administration.
Enrofloxacin is a widely utilized antibiotic in veterinary
medicine that has antibacterial activity against both gram-
negative and gram-positive organisms [21,22]. Enrofloxacin
is generally regarded as not only an efficacious antibiotic,
but also a safe drug [23].This treatment regimen was suggested
successful in controlling Shigella in rhesus monkey based on
clinical signs and successive cultures of rectal swabs from
the infected monkey. In summary, our case suggests that a
newly acquired rhesus monkey can be infected by Shigella
flexneri, even with previous screening of bacterial and parasitic
pathogens by the exporting country. It is considered that the
infected monkey was an asymptomatic carrier and revealed
clinical symptoms due to stressful environmental changes.
Regular screening tests, control of transmission and aggressive
treatment for this pathogen are essential for preservation of
healthy nonhuman primate facilities.
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